On Friday, Elon Musk said Eli Lilly (NYSE:LLY) has "some banger drugs coming out”, after the drugmaker’s CEO Dave Ricks took on a “bet” responding to venture investor Vinod Khosla on X. Ricks Answers Big Biotech Skeptics Ricks’ reply came after Khosla commented on Musk’s post, which shared a thread by biotech enthusiast Mgoes about potential breakthroughs in human biology.
“Agree 100% but unlikely it will come from the big bio companies,” said Khosla. ” Eli Lilly has some banger drugs coming out!
" Neither Musk nor Ricks named specific drugs. If you look closely enough, breakthroughs in everything are accelerating exponentially.
An exponential always starts off looking small. co/cwXQqooR7r— Elon Musk (@elonmusk) October 29, 2026 Viral Biotech Thread Sparked the Exchange The exchange began with a post earlier this week by X user "Mgoes," who said a massive shift is underway in human biology.
He said he does not work at Lilly, Novo Nordisk A/S (NYSE:NVO) or other large drugmakers. ’s (NYSE:MRK) Keytruda alone in a 1,137-patient melanoma Phase 3.
Retatrutide was the only drug on the list linked to Lilly. The day after Mgoes’ post, Lilly announced that the once-weekly drug had met its primary goal in a Phase 3 trial comparing it with Novo’s Ozempic 2 mg.
The trial involved 1,298 adults with Type 2 diabetes. 4%) on Ozempic.
Blood sugar levels also improved. 8% with Ozempic.
Read Also: Meta's $145 Billion AI Spending Plan Raises Credit Concerns as S&P Global Turns Outlook Negative: ‘Less Certain That It Will Curtail Its Spending’ Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
